RJFSA
DRNA

Raymond James Financial Services Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,010
Closed -$560K – 3447
2021
Q2 		$560K Buy
15,010
+1,115
+8% +$34.2K ﹤0.01% 2297
2021
Q1 		$355K Buy
+13,895
New +$355K ﹤0.01% 2520

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Raymond James Financial Services Advisors's DRNA Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 15,010 shares — an estimated $560K sold.

Raymond James Financial Services Advisors first reported a position in DRNA in Q1 2021 and held it in 2 quarters. The position peaked at $560K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 15,010 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $560K.
  • Raymond James Financial Services Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2021 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $560K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.